Civica Rx, a hospital-funded generic drug company has just announced that it has entered into an agreement with drugmaker Xellia Pharmaceuticals to manufacture and supply the IV antibiotics vancomycin and daptomycin.
Civica is taking steps the towards address drug shortages and the rising cost of generics. This move will benefit 900 hospitals as patients in the VA.
Xellia will expand its production of the antibiotics and Civica will buy at set volumes and prices over the next 5 years. This will generate additional guaranteed revenue for Xellia.